Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
OA03 - Promising Antibody-Drug Conjugate and Cytotoxic Therapy in NSCLC
- 10:30 - 11:30
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
-
+
OA03.01 - Chair
10:30 - 10:30 | Presenter: Jhanelle Elaine Gray
- Abstract
No abstract available for this presentation
-
+
OA03.02 - Chair
10:30 - 10:30 | Presenter: Sukhmani K. Padda
- Abstract
No abstract available for this presentation
-
+
OA03.03 - Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study
10:30 - 10:40 | Presenter: Alex I. Spira
- Abstract
Loading... -
+
OA03.04 - Efficacy and Safety of the Novel HER3 Directed Antibody Drug Conjugate Patritumab Deruxtecan (HER3-DXd; U3-1402) in EGFR-mutated NSCLC
10:40 - 10:50 | Presenter: Helena Yu
- Abstract
Loading... -
+
OA03.05 - Phase III Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
10:50 - 11:00 | Presenter: Atsushi Nakamura
- Abstract
Loading... -
+
OA03.06 - Discussant
11:00 - 11:10 | Presenter: Ignatius Ou
- Abstract
No abstract available for this presentation
-
+
OA03.07 - Live Q&A
11:10 - 11:30
- Abstract
No abstract available for this presentation
-
+
ES04 - Strategies to Increase Cure Rates in Stage III NSCLC: Optimising Checkpoint Inhibitors and Beyond
- 11:45 - 12:45
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Educational Session
- Track: Locoregional and Oligometastatic Disease
-
+
ES04.01 - Navigating the Evaluation of Novel Systemic Agents in Stage III Disease
11:45 - 12:05 | Presenter: Karen Kelly
- Abstract
Loading... -
+
ES04.02 - Biology Guided Adaptive Radiation Therapy (BigART) and Personalized Immunotherapy in Unresectable Stage
12:05 - 12:25 | Presenter: Feng-Ming (Spring) Kong
- Abstract
No abstract available for this presentation
-
+
ES04.03 - Extending Durvalumab Maintenance to Special Populations
12:25 - 12:45 | Presenter: Raffaele Califano
- Abstract
No abstract available for this presentation
-
+
MA01 - Novel Systemic Treatment in NSCLC
- 11:45 - 12:45
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
-
+
MA01.01 - Chair
11:45 - 11:45 | Presenter: Thanyanan Reungwetwattana
- Abstract
No abstract available for this presentation
-
+
MA01.02 - Chair
11:45 - 11:45 | Presenter: Julia K Rotow
- Abstract
No abstract available for this presentation
-
+
MA01.03 - The Role of Gut Microbiome in the Efficacy of Chemotherapy in Patients With Locally Advanced and Advanced Lung Cancer
11:45 - 11:50 | Presenter: Zhe Zhao
- Abstract
Loading... -
+
MA01.04 - A Randomized Study Comparing Cisplatin/Paclitaxel Liposome vs Cisplatin/Gemcitabine in Chemonaive, Advanced Squamous NSCLC
11:50 - 11:55 | Presenter: Caicun Zhou
- Abstract
Loading... -
+
MA01.05 - Clinical Efficacy and Safety of Pemetrexed With or Without Either Bevacizumab or Pembrolizumab in Patients With Metastatic NSCLC
11:55 - 12:00 | Presenter: Wang Chun Kwok
- Abstract
Loading... -
+
MA01.06 - Phase 2 of Pro-Autophagic Drug ABTL0812 in Combination With First-Line Paclitaxel and Carboplatin in IIIb/IV Squamous NSCLC
12:00 - 12:05 | Presenter: Joaquim Bosch-Barrera
- Abstract
Loading... -
+
MA01.07 - Discussant
12:05 - 12:10 | Presenter: Benjamin Levy
- Abstract
No abstract available for this presentation
-
+
MA01.08 - Gemcitabine Plus Capecitabine in Patients With Primary Pulmonary Lymphoepithelioma-Like Carcinoma Previously Treated With Chemotherapy
12:10 - 12:15 | Presenter: Ying Liang
- Abstract
Loading... -
+
MA01.09 - Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504)
12:15 - 12:20 | Presenter: Saad A. Khan
- Abstract
Loading... -
+
MA01.10 - MDM2 Inhibitor APG-115 Suppresses Cell Proliferation and Tumor Growth in Preclinical Models Of NSCLC Harboring STK11 Mutations
12:20 - 12:25 | Presenter: Hao Sun
- Abstract
Loading... -
+
MA01.11 - CD47 Agonist Peptide PKHB1 Induced Cell Death in NSCLC via Triggering Endoplasmic Reticulum Stress
12:25 - 12:30 | Presenter: Jiani Ye
- Abstract
Loading... -
+
MA01.12 - Discussant
12:30 - 12:35 | Presenter: Will Lockwood
- Abstract
No abstract available for this presentation
-
+
MA01.13 - Live Q&A
12:35 - 12:45
- Abstract
No abstract available for this presentation
-
+
OA04 - New Data from Rare EGFR Alterations
- 11:45 - 12:45
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Targeted Therapy - Clinically Focused
-
+
OA04.01 - Chair
11:45 - 11:45 | Presenter: Hossein Borghaei
- Abstract
No abstract available for this presentation
-
+
OA04.02 - Chair
11:45 - 11:45 | Presenter: Jason Porter
- Abstract
No abstract available for this presentation
-
+
OA04.03 - Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations
11:45 - 11:55 | Presenter: Caicun Zhou
- Abstract
Loading... -
+
OA04.04 - Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer
11:55 - 12:05 | Presenter: Joshua K. Sabari
- Abstract
Loading... -
+
OA04.05 - Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01
12:05 - 12:15 | Presenter: Kazuhiko Nakagawa
- Abstract
Loading... -
+
OA04.06 - Neratinib in Pretreated EGFR Exon 18-Mutant Non-Small Cell Lung Cancer (NSCLC): Initial Findings From the SUMMIT Basket Trial
12:15 - 12:25 | Presenter: Valentina Boni
- Abstract
Loading... -
+
OA04.07 - Discussant
12:25 - 12:35 | Presenter: Gillianne Geet Yi Lai
- Abstract
No abstract available for this presentation
-
+
OA04.08 - Live Q&A
12:35 - 12:45
- Abstract
No abstract available for this presentation
-
+
IS08 - Industry Symposium Sponsored by Janssen Oncology: What the Future Holds for Advanced NSCLC Patients with Resistance to EGFR TKIs
- 13:00 - 14:00
- 1/29/2021
- Location: Industry Symposia Auditorium (via Industry Hub)
- Not for CME Credit
- Type: Industry Symposium
- Track:
-
+
IS08.01 - Welcome and Introductions
13:00 - 13:05 | Presenter: Tetsuya Mitsudomi
- Abstract
No abstract available for this presentation
-
+
IS08.02 - A Light at the End of the Tunnel - Hope for Patients With EGFR Exon20 Insertion Mutations
13:05 - 13:25 | Presenter: Byoung Chul Cho
- Abstract
No abstract available for this presentation
-
+
IS08.03 - The Dawn of a New Era - Novel Treatments for Patients With TKI Resistant Disease With Common EGFR Mutations
13:25 - 13:45 | Presenter: Enriqueta Felip
- Abstract
No abstract available for this presentation
-
+
IS08.04 - Live Q&A: From Information to Transformation - Navigating the Evidence With Experience Sharing in a Live Forum to Improve Patient Care
13:45 - 14:00
- Abstract
No abstract available for this presentation
-
+
IS09 - Industry Symposium Sponsored by Pfizer Oncology: Expert Question Time: ALK+ NSCLC
- 13:00 - 14:00
- 1/29/2021
- Location: Industry Symposia Auditorium (via Industry Hub)
- Not for CME Credit
- Type: Industry Symposium
- Track:
-
+
IS09.01 - Welcome and Introduction
13:00 - 13:05 | Presenter: Seng Weng Wong
- Abstract
No abstract available for this presentation
-
+
IS09.02 - Navigating Recent Clinical Data for ALK + TKIS
13:05 - 13:45 | Presenter: Thanyanan Reungwetwattana
- Abstract
No abstract available for this presentation
-
+
IS09.02 - Selecting Treatment and Management of ALK+ NSCLC
13:45 - 13:45 | Presenter: Nick Pavlakis
- Abstract
No abstract available for this presentation
-
+
IS09.02 - The Importance of Managing CNS Disease
13:45 - 13:45 | Presenter: John Chang
- Abstract
No abstract available for this presentation
-
+
IS09.02 - The Future of ALK+ NSCLC
13:45 - 13:45 | Presenter: Nir Peled
- Abstract
No abstract available for this presentation
-
+
IS09.03 - Q&A
13:45 - 13:58
- Abstract
No abstract available for this presentation
-
+
IS09.04 - Summary, Thank You and Close
13:58 - 14:00 | Presenter: Seng Weng Wong
- Abstract
No abstract available for this presentation
-
+
IS10 - Industry Symposium Sponsored by Bristol Myers Squibb: Thoracic Cancers, New Developments with IO
- 13:00 - 14:00
- 1/29/2021
- Location: Industry Symposia Auditorium (via Industry Hub)
- Not for CME Credit
- Type: Industry Symposium
- Track:
-
+
IS10.01 - Welcome and Introductions
13:00 - 13:05 | Presenter: Virginie Westeel
- Abstract
No abstract available for this presentation
-
+
IS10.02 - What Is the Role of IO in Non-Metastatic NSCLC?
13:05 - 13:20 | Presenter: Virginie Westeel
- Abstract
No abstract available for this presentation
-
+
IS10.03 - IO in the Treatment of Metastatic NSCLC, Where Are We Now?
13:20 - 13:35 | Presenter: Julie Brahmer
- Abstract
No abstract available for this presentation
-
+
IS10.04 - Non-Metastatic and Metastatic NSCLC Q&A
13:35 - 13:40 | Presenter: Virginie Westeel, Julie Brahmer
- Abstract
No abstract available for this presentation
-
+
IS10.05 - What Is I-O’s Impact on the Treatment Paradigm for Mesothelioma Patients?
13:40 - 13:55 | Presenter: Nicolas Girard
- Abstract
No abstract available for this presentation
-
+
IS10.06 - Mesothelioma Q&A and Closing Remarks
13:55 - 14:00 | Presenter: Nicolas Girard, Virginie Westeel
- Abstract
No abstract available for this presentation
-
+
ES05 - Value in Lung Cancer, from Screening to Treatment
- 14:15 - 15:15
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Educational Session
- Track: Health Services Research/Health Economics
-
+
ES05.01 - Chair
14:15 - 14:15 | Presenter: Antonio Calles
- Abstract
No abstract available for this presentation
-
+
ES05.02 - Chair
14:15 - 14:15 | Presenter: Lucinda Morris
- Abstract
No abstract available for this presentation
-
+
ES05.03 - Radiation Oncology: Value and Innovation
14:15 - 14:25 | Presenter: Fumiko Ladd Chino
- Abstract
Loading... -
+
ES05.04 - Lung Cancer Screening in Lower Resource Settings
14:25 - 14:35 | Presenter: Ricardo Santos
- Abstract
No abstract available for this presentation
-
+
ES05.05 - Age, Gender and Ethnicity: Disparities in Lung Cancer
14:35 - 14:45 | Presenter: Linda Coate
- Abstract
No abstract available for this presentation
-
+
ES05.06 - Molecular Testing, Targeted Agents and Immunotherapy in Lung Cancer: Are They Worth the Cost?
14:45 - 14:55 | Presenter: Gilberto Lopes
- Abstract
No abstract available for this presentation
-
+
ES05.07 - Defining Value and Common Sense in Lung Cancer
14:55 - 15:05 | Presenter: Bishal Gyawali
- Abstract
Loading... -
+
ES05.08 - Live Q&A
15:05 - 15:15
- Abstract
No abstract available for this presentation
-
+
ES06 - Perioperative Therapy for Early Stage NSCLC
- 14:15 - 15:15
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Educational Session
- Track: Early Stage/Localized Disease
-
+
ES06.01 - Neoadjuvant IO Monotherapy vs. Chemo-IO
14:15 - 14:30 | Presenter: Mariano Provencio
- Abstract
Loading... -
+
ES06.02 - Radiation and IO for Operable Early Stage NSCLC
14:30 - 14:45 | Presenter: Suresh Senan
- Abstract
Loading... -
+
ES06.03 - Neoadjvuant and Adjuvant Targeted Therapies
14:45 - 15:00 | Presenter: Wen-zhao Zhong
- Abstract
No abstract available for this presentation
-
+
ES06.04 - MPR and pCR as Primary Endpoints in Neoadjuvant Trials
15:00 - 15:15 | Presenter: Noriko Motoi
- Abstract
Loading...
-
+
MA02 - Technological Advances in Diagnostics, Imaging and Therapeutics for Lung Cancer
- 14:15 - 15:15
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Diagnostics and Interventional Pulmonology
-
+
MA02.01 - Chair
14:15 - 14:15 | Presenter: Pieter Edsge Postmus
- Abstract
No abstract available for this presentation
-
+
MA02.02 - Chair
14:15 - 14:15 | Presenter: David Paul Carbone
- Abstract
No abstract available for this presentation
-
+
MA02.04 - Initial Experience of Hybrid Operating Room Cone-Beam CT Guided Bronchoscopic Microwave Thermal Ablation of Peripheral Small Lung Lesions
14:15 - 14:20 | Presenter: Joyce Chan
- Abstract
Loading... -
+
MA02.05 - NAVIGATE 24-Month Results: Electromagnetic Navigation Bronchoscopy for Pulmonary Lesions at 37 Centers in Europe and the US
14:20 - 14:25 | Presenter: Erik Folch
- Abstract
Loading... -
+
MA02.07 - Discussant
14:25 - 14:30 | Presenter: Kazuhiro Yasufuku
- Abstract
No abstract available for this presentation
-
+
MA02.08 - Computed Tomography Attenuation Value as Considerable Predictor for Malignancy in Clinical T1 Lung Adenocarcinoma
14:30 - 14:35 | Presenter: Zhen-Bin Qiu
- Abstract
Loading... -
+
MA02.09 - Analysis of Targets for Lung Stereotactic Body Radiotherapy with Clinical Four Dimension (4D) Computed Tomography (CT)
14:35 - 14:40 | Presenter: Kaile Li
- Abstract
Loading... -
+
MA02.10 - Deriving Pulmonary Perfusion Images from 4DCT Using Deep Learning
14:40 - 14:45 | Presenter: Daniela Lozano
- Abstract
Loading... -
+
MA02.11 - Timing and Site-specific Recurrence Pattern for Resected Lung Adenocarcinoma and Association with Driver Gene Mutations
14:45 - 14:50 | Presenter: Deng Chaoqiang
- Abstract
Loading... -
+
MA02.12 - Discussant
14:50 - 14:55 | Presenter: Tobias Peikert
- Abstract
No abstract available for this presentation
-
+
MA02.13 - Live Q&A
14:55 - 15:15
- Abstract
No abstract available for this presentation
first
prev
